Envista | Evaluate

January 11, 2022

Diabetes device makers lead the smaller medtechs

Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.

Smaller medtechs suffer, but not from Covid-19

Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.

January 06, 2021

Dentsply sees clear advantages to $1bn Byte deal

July 08, 2020

Smaller device makers put in a muted performance

Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.